Sugi Predict

Sugi Predict / Compounds / SCHEMBL17595754

SCHEMBL17595754

SCHEMBL17595754

Cn1ncc2cccc(CBr)c21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPC5 Q9UL62 1/20 0.39
▸ SLC16A3 O15427 1/20 0.34
▸ SLC16A1 P53985 1/20 0.34
▸ BRD4 O60885 3/20 0.33
▸ HPGD P15428 2/20 0.33
▸ HTT P42858 2/20 0.33
▸ ALDH1A1 P00352 2/20 0.33
▸ BRD9 Q9H8M2 2/20 0.33
▸ ACKR3 P25106 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ GLA P06280 1/20 0.33
▸ GAA P10253 1/20 0.33
▸ CASP1 P29466 1/20 0.33
▸ CASP7 P55210 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ HSD17B10 Q99714 1/20 0.33
▸ EGFR P00533 1/20 0.33
▸ NAMPT P43490 1/20 0.32
▸ KAT2B Q92831 2/20 0.32
▸ BPTF Q12830 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20757767 0.84 TRPC5 (0.42) TRPC5SLC16A3SLC16A1BRD4HPGD
SCHEMBL20757990 0.83 GABRA1 (0.43) TRPC5SLC16A3SLC16A1HPGDHTT
SCHEMBL31038878 0.82 BPTF (0.40) TRPC5SLC16A3SLC16A1BRD4HPGD
SCHEMBL22481545 0.82 TRPC5 (0.41) TRPC5SLC16A3SLC16A1BRD4HPGD
SCHEMBL30006444 0.76 LGMN (0.38) TRPC5SLC16A3SLC16A1HTTNAMPT
SCHEMBL2383365 0.76 NOS1 (0.37) TRPC5HPGDHTTALDH1A1ACKR3
SCHEMBL31668718 0.73 ADRA2A (0.45) HPGDHTTALDH1A1ACKR3KDM4E
SCHEMBL8030619 0.73 ADRA2A (0.45) HPGDHTTALDH1A1ACKR3KDM4E
SCHEMBL18368382 0.73 GABRA1 (0.38) HPGDHTTALDH1A1ACKR3KDM4E
SCHEMBL21509553 0.73 TRPC5 (0.35) TRPC5HPGDHTTALDH1A1ACKR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260055062-A1 HETEROCYCLIC INHIBITORS OF MCT4 Vettore, LLC 2026-02-26 — — US disclosed
US-12492171-B2 Heterocyclic inhibitors of MCT4 Vettore, LLC (US) 2025-12-09 — — US disclosed
EP-4442318-A2 HETEROCYCLIC INHIBITORS OF MCT4 Vettore, LLC (US) 2024-10-09 — — EP disclosed
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF CORNELL UNIVERSITY (US) 2024-07-18 — — US disclosed
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF CORNELL UNIVERSITY (US) 2024-07-18 — — US disclosed
US-20220251047-A1 HETEROCYCLIC INHIBITORS OF MCT4 Vettore, LLC 2022-08-11 — — US disclosed
US-11332459-B2 Benzimidazole derivatives and their uses TEIJIN PHARMA LIMITED (JP) 2022-05-17 — — US disclosed
US-11292767-B2 Heterocyclic inhibitors of MCT4 Vettore, LLC (US) 2022-04-05 — — US disclosed
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES AMGEN INC. (US) 2020-10-01 — — US disclosed
US-20190112275-A1 HETEROCYCLIC INHIBITORS OF MCT4 Vettore, LLC 2019-04-18 — — US disclosed
US-20180162822-A1 HETEROCYCLIC INHIBITORS OF MCT4 Vettore, LLC 2018-06-14 — — US disclosed
US-9920075-B2 Triazolopyridine and triazolopyrimidine inhibitors of myeloperoxidase BRISTOL-MYERS SQUIBB COMPANY (US) 2018-03-20 — — US disclosed
US-20170247396-A1 TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL MYERS SQUIBB CO (US) 2017-08-31 — — US disclosed
EP-3191485-A1 TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE Bristol-Myers Squibb Company (US) 2017-07-19 — — EP disclosed
WO-2016040417-A1 TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE BRISTOL-MYERS SQUIBB COMPANY (US) 2016-03-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12492171-B2 Heterocyclic inhibitors of MCT4 SLC16A3, SLC16A1, MCTS1 TRPC5 1188/4885SLC16A3 1/4885SLC16A1 2/4885
US-20170247396-A1 TRIAZOLOPYRIDINE AND TRIAZOLOPYRIMIDINE INHIBITORS OF MYELOPEROXIDASE EPX, MPO, SERPINB1 TRPC5 1709/4885SLC16A3 4362/4885SLC16A1 4033/4885
US-20240239774-A1 SOLUBLE ADENYLYL CYCLASE (SAC) INHIBITORS AND USES THEREOF UACA, ADCYAP1R1, ADCY1 TRPC5 1811/4885SLC16A3 1469/4885SLC16A1 937/4885
US-11292767-B2 Heterocyclic inhibitors of MCT4 SLC16A3, SLC16A1, MCTS1 TRPC5 1188/4885SLC16A3 1/4885SLC16A1 2/4885
US-20200308145-A1 BENZIMIDAZOLE DERIVATIVES AND THEIR USES TRPC6, TRPV6, TRPM6 TRPC5 12/4885SLC16A3 911/4885SLC16A1 950/4885
US-20190112275-A1 HETEROCYCLIC INHIBITORS OF MCT4 SLC16A3, SLC16A1, MCTS1 TRPC5 1188/4885SLC16A3 1/4885SLC16A1 2/4885
US-20220251047-A1 HETEROCYCLIC INHIBITORS OF MCT4 SLC16A3, SLC16A1, MCTS1 TRPC5 1188/4885SLC16A3 1/4885SLC16A1 2/4885
US-20180162822-A1 HETEROCYCLIC INHIBITORS OF MCT4 SLC16A3, SLC16A1, MCTS1 TRPC5 1188/4885SLC16A3 1/4885SLC16A1 2/4885
US-11332459-B2 Benzimidazole derivatives and their uses TRPC6, TRPV6, TRPM6 TRPC5 12/4885SLC16A3 911/4885SLC16A1 950/4885
US-20260055062-A1 HETEROCYCLIC INHIBITORS OF MCT4 SLC16A1, SLC16A3, SLC16A7 TRPC5 444/4885SLC16A3 2/4885SLC16A1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.